Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer

Shin Narai, Masahiko Watanabe, Hirotoshi Hasegawa, Hideki Nishibori, Takashi Endo, Tetsuro Kubota, Masaki Kitajima

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Transforming growth factor β1 (TGF-β1) is thought to be involved in cancer growth and progression. TGF-β1 changes to its active form after being secreted in its latent form. Our aim was to clarify the significance of plasma concentrations of active and total TGF-β1 of patients with colorectal cancer. Plasma concentrations of active and total TGF-β1 in 45 patients with colorectal cancer and 23 healthy volunteers were measured using ELISA and the activation rate (ratio of active to total TGF-β1) was determined. Plasma concentrations of active TGF-β1 (21.9 ± 12.8 pg/ml) were significantly higher in patients with colorectal cancer than in healthy volunteers (9.9 ± 5.9 pg/ml; p < 0.001, Welch's t-test). Concentration of total TGF-β1 was also significantly higher for patients with colorectal cancer (18.0 ± 13.0 ng/ml vs. 11.1 ± 6.4 ng/ml; p < 0.01, Welch's t-test). However, there was no significant difference in the TGF->1 activation rate between the 2 groups. There was a correlation between Dukes' stage and plasma concentration of active or total TGF-β1 (p < 0.01, Spearman's rank correlation test) and on day 7 the active TGF-β1 levels for patients recovering from curative resection were similar to those of the control group of healthy volunteers. These results suggest that active TGF-β1 might be used as a tumor marker for colorectal cancer.

Original languageEnglish
Pages (from-to)508-511
Number of pages4
JournalInternational Journal of Cancer
Volume97
Issue number4
DOIs
Publication statusPublished - 2002 Feb 1

Fingerprint

Transforming Growth Factors
Tumor Biomarkers
Colorectal Neoplasms
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Control Groups
Growth

Keywords

  • Colorectal cancer
  • Dukes' stage
  • Growth factor
  • Transforming growth factor β1
  • Tumor marker

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Narai, S., Watanabe, M., Hasegawa, H., Nishibori, H., Endo, T., Kubota, T., & Kitajima, M. (2002). Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer. International Journal of Cancer, 97(4), 508-511. https://doi.org/10.1002/ijc.1631

Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer. / Narai, Shin; Watanabe, Masahiko; Hasegawa, Hirotoshi; Nishibori, Hideki; Endo, Takashi; Kubota, Tetsuro; Kitajima, Masaki.

In: International Journal of Cancer, Vol. 97, No. 4, 01.02.2002, p. 508-511.

Research output: Contribution to journalArticle

Narai, S, Watanabe, M, Hasegawa, H, Nishibori, H, Endo, T, Kubota, T & Kitajima, M 2002, 'Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer', International Journal of Cancer, vol. 97, no. 4, pp. 508-511. https://doi.org/10.1002/ijc.1631
Narai, Shin ; Watanabe, Masahiko ; Hasegawa, Hirotoshi ; Nishibori, Hideki ; Endo, Takashi ; Kubota, Tetsuro ; Kitajima, Masaki. / Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer. In: International Journal of Cancer. 2002 ; Vol. 97, No. 4. pp. 508-511.
@article{4d67f2a3dd41477eb5751dc6ed77ad3f,
title = "Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer",
abstract = "Transforming growth factor β1 (TGF-β1) is thought to be involved in cancer growth and progression. TGF-β1 changes to its active form after being secreted in its latent form. Our aim was to clarify the significance of plasma concentrations of active and total TGF-β1 of patients with colorectal cancer. Plasma concentrations of active and total TGF-β1 in 45 patients with colorectal cancer and 23 healthy volunteers were measured using ELISA and the activation rate (ratio of active to total TGF-β1) was determined. Plasma concentrations of active TGF-β1 (21.9 ± 12.8 pg/ml) were significantly higher in patients with colorectal cancer than in healthy volunteers (9.9 ± 5.9 pg/ml; p < 0.001, Welch's t-test). Concentration of total TGF-β1 was also significantly higher for patients with colorectal cancer (18.0 ± 13.0 ng/ml vs. 11.1 ± 6.4 ng/ml; p < 0.01, Welch's t-test). However, there was no significant difference in the TGF->1 activation rate between the 2 groups. There was a correlation between Dukes' stage and plasma concentration of active or total TGF-β1 (p < 0.01, Spearman's rank correlation test) and on day 7 the active TGF-β1 levels for patients recovering from curative resection were similar to those of the control group of healthy volunteers. These results suggest that active TGF-β1 might be used as a tumor marker for colorectal cancer.",
keywords = "Colorectal cancer, Dukes' stage, Growth factor, Transforming growth factor β1, Tumor marker",
author = "Shin Narai and Masahiko Watanabe and Hirotoshi Hasegawa and Hideki Nishibori and Takashi Endo and Tetsuro Kubota and Masaki Kitajima",
year = "2002",
month = "2",
day = "1",
doi = "10.1002/ijc.1631",
language = "English",
volume = "97",
pages = "508--511",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Significance of transforming growth factor β1 as a new tumor marker for colorectal cancer

AU - Narai, Shin

AU - Watanabe, Masahiko

AU - Hasegawa, Hirotoshi

AU - Nishibori, Hideki

AU - Endo, Takashi

AU - Kubota, Tetsuro

AU - Kitajima, Masaki

PY - 2002/2/1

Y1 - 2002/2/1

N2 - Transforming growth factor β1 (TGF-β1) is thought to be involved in cancer growth and progression. TGF-β1 changes to its active form after being secreted in its latent form. Our aim was to clarify the significance of plasma concentrations of active and total TGF-β1 of patients with colorectal cancer. Plasma concentrations of active and total TGF-β1 in 45 patients with colorectal cancer and 23 healthy volunteers were measured using ELISA and the activation rate (ratio of active to total TGF-β1) was determined. Plasma concentrations of active TGF-β1 (21.9 ± 12.8 pg/ml) were significantly higher in patients with colorectal cancer than in healthy volunteers (9.9 ± 5.9 pg/ml; p < 0.001, Welch's t-test). Concentration of total TGF-β1 was also significantly higher for patients with colorectal cancer (18.0 ± 13.0 ng/ml vs. 11.1 ± 6.4 ng/ml; p < 0.01, Welch's t-test). However, there was no significant difference in the TGF->1 activation rate between the 2 groups. There was a correlation between Dukes' stage and plasma concentration of active or total TGF-β1 (p < 0.01, Spearman's rank correlation test) and on day 7 the active TGF-β1 levels for patients recovering from curative resection were similar to those of the control group of healthy volunteers. These results suggest that active TGF-β1 might be used as a tumor marker for colorectal cancer.

AB - Transforming growth factor β1 (TGF-β1) is thought to be involved in cancer growth and progression. TGF-β1 changes to its active form after being secreted in its latent form. Our aim was to clarify the significance of plasma concentrations of active and total TGF-β1 of patients with colorectal cancer. Plasma concentrations of active and total TGF-β1 in 45 patients with colorectal cancer and 23 healthy volunteers were measured using ELISA and the activation rate (ratio of active to total TGF-β1) was determined. Plasma concentrations of active TGF-β1 (21.9 ± 12.8 pg/ml) were significantly higher in patients with colorectal cancer than in healthy volunteers (9.9 ± 5.9 pg/ml; p < 0.001, Welch's t-test). Concentration of total TGF-β1 was also significantly higher for patients with colorectal cancer (18.0 ± 13.0 ng/ml vs. 11.1 ± 6.4 ng/ml; p < 0.01, Welch's t-test). However, there was no significant difference in the TGF->1 activation rate between the 2 groups. There was a correlation between Dukes' stage and plasma concentration of active or total TGF-β1 (p < 0.01, Spearman's rank correlation test) and on day 7 the active TGF-β1 levels for patients recovering from curative resection were similar to those of the control group of healthy volunteers. These results suggest that active TGF-β1 might be used as a tumor marker for colorectal cancer.

KW - Colorectal cancer

KW - Dukes' stage

KW - Growth factor

KW - Transforming growth factor β1

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0036466883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036466883&partnerID=8YFLogxK

U2 - 10.1002/ijc.1631

DO - 10.1002/ijc.1631

M3 - Article

VL - 97

SP - 508

EP - 511

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -